SCNI vs. ACOR, TCBP, ACORQ, GMDAQ, WINT, ALBT, ELOX, KRBP, SPRC, and SBFM
Should you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Acorda Therapeutics (ACOR), TC Biopharm (TCBP), Acorda Therapeutics (ACORQ), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), Avalon GloboCare (ALBT), Eloxx Pharmaceuticals (ELOX), Kiromic BioPharma (KRBP), SciSparc (SPRC), and Sunshine Biopharma (SBFM). These companies are all part of the "medical" sector.
Scinai Immunotherapeutics (NASDAQ:SCNI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.
Scinai Immunotherapeutics has higher earnings, but lower revenue than Acorda Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
Scinai Immunotherapeutics has a beta of 2.45, suggesting that its stock price is 145% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.
Acorda Therapeutics received 472 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users.
Scinai Immunotherapeutics has a net margin of 0.00% compared to Acorda Therapeutics' net margin of -214.95%. Scinai Immunotherapeutics' return on equity of 0.00% beat Acorda Therapeutics' return on equity.
58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 12.7% of Acorda Therapeutics shares are held by institutional investors. 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 2.6% of Acorda Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Scinai Immunotherapeutics had 2 more articles in the media than Acorda Therapeutics. MarketBeat recorded 3 mentions for Scinai Immunotherapeutics and 1 mentions for Acorda Therapeutics. Acorda Therapeutics' average media sentiment score of 0.00 beat Scinai Immunotherapeutics' score of -0.67 indicating that Acorda Therapeutics is being referred to more favorably in the news media.
Summary
Scinai Immunotherapeutics beats Acorda Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Scinai Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scinai Immunotherapeutics Competitors List
Related Companies and Tools
